Increased induction of apoptosis by *Propionibacterium freudenreichii* TL133 in colonic mucosal crypts of human microbiota-associated rats treated with 1,2-dimethylhydrazine

Annaïg Lan¹,², Aurélia Bruneau³, Martine Bensaada³, Catherine Philippe³, Pascale Bellaud⁴, Sylvie Rabot⁵ and Gwénaël Jan¹*  
¹INRA, Agrocampus Rennes, UMR1253 Science et Technologie du Lait et de l’Oeuf, Rennes F-35000, France  
²Laboratoires Standa, Caen F-14050, France  
³INRA, UR910 Ecologie et Physiologie du Système Digestif, Jouy-en-Josas F-78350, France  
⁴Laboratoire d’Anatomie Pathologique, Faculté de Médecine, Université de Rennes 1, Rennes F-35000, France

(Received 13 November 2007 – Revised 10 March 2008 –Accepted 11 March 2008 – First published online 9 May 2008)

*Propionibacterium freudenreichii*, a food-grade bacterium able to kill colon cancer cell lines in *vitro* by apoptosis, may exert an anticarcinogenic effect in *vivo*. To assess this hypothesis, we administered daily 2 × 10¹⁰ colony-forming units (CFU) of *P. freudenreichii* TL133 to human microbiota-associated (HMA) rats for 18 d. Either saline or 1,2-dimethylhydrazine (DMH) was also administered on days 13 and 17 and rats were killed on day 19. The levels of apoptosis and proliferation in the mid and distal colon were assessed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labelling (TUNEL) and proliferating cell nuclear antigen (PCNA) immunolabelling, respectively. The administration of *P. freudenreichii* TL133 significantly increased the number of apoptotic cells in DMH-treated rats compared to those given DMH only (P < 0.01). Furthermore, propionibacteria were able to decrease the proliferation index in the distal colon after treatment with DMH (P < 0.01). Conversely, propionibacteria alone did not exert such an effect on healthy colonic mucosa. *P. freudenreichii* TL133 thus facilitated the elimination of damaged cells by apoptosis in the rat colon after genotoxic insult and may play a protective role against colon cancer.

**Probiotics: Colon carcinogenesis: Apoptosis: Gnotobiotic rats**

Colon cancer constitutes a growing health concern in developed countries. Indeed, it is one of the major causes of death by cancer in the Western world. It is the third most frequent cancer in men, after prostate and lung, and the second most common in women, after breast. The increased incidence of this disease is likely to be linked with following a Western lifestyle, in particular the Western diet and physical inactivity(1,2). An appropriate diet may prevent three out of four cases of colorectal cancer(3). Because colon cancer is thus a preventable disease, the impact of food components on carcinogenesis of the colon has been investigated in a considerable number of studies during the last few decades. In particular, there has been a growing interest in the ability of probiotics to inhibit the development of cancer. A probiotic is generally defined as ’a live microorganism which, when administered in adequate amounts, confers a health benefit to the host’(4). Previous studies have established that the ingestion of certain strains of bifidobacteria or lactobacilli, either alone or in combination with a prebiotic, reduces the incidence of tumour and/or colonic pre-neoplastic lesions, aberrant crypt foci, in animals treated with carcinogens(5–10). However, the precise mechanisms by which probiotics act on the colonic mucosa are still unclear(11,12). Possible mechanisms by which probiotics could have anti-cancer effects include an enhancement of the host’s immune response, the binding or degrading of potential carcinogens, the production of antitumourigenic compounds, the alteration of the intestinal microbiota and its metabolic activities, or the alteration of physiological conditions in the colon, for instance pH or the concentration and profile of bile acids(12–14).

Certain food components might be considered as having a preventive effect against colon cancer by favouring the apoptotic depletion of DNA-damaged cells which might be likely to progress to malignancy. Acquired resistance towards apoptosis is a hallmark of cancer(15). One possible mechanism by which probiotics could have anti-cancer effects is an enhancement of the host’s immune response, the binding or degrading of potential carcinogens, the production of antitumourigenic compounds, the alteration of the intestinal microbiota and its metabolic activities, or the alteration of physiological conditions in the colon, for instance pH or the concentration and profile of bile acids(12–14).

...
may reduce the probability of cancer development\(^{(20)}\). So far, only a few dietary compounds such as the glucosinolate sinigrin, n-3 PUFA, chicory fructans, or resistant starch combined with *Bifidobacterium lactis*, have been reported to be able to facilitate elimination of damaged cells by apoptosis in rat colon between 6 and 72 h after genotoxic insult induced by a carcinogen\(^{(20–25)}\).

The pro-apoptotic potential of dairy propionibacteria (PAB) was here investigated *in vivo*. Several species, including *Propionibacterium freudenreichii* probiotic strain SH41, have previously been shown to kill human colon adenocarcinoma cells *in vitro*\(^{(26)}\). They induce apoptosis via their metabolites, one of which is propionate, that acts on cancer cells and leads to cell cycle arrest in the G2/M phase, generation of reactive oxygen species, Bax translocation, mitochondrial depolarization, activation of caspases, and chromatin condensation and fractionation\(^{(24,25)}\). Their ability to do so confers them anti-cancer potential. However, the specificity of induction of apoptosis has not yet been characterised, and doing so is crucial, for ideally only malignant cells should be killed and not healthy ones. The occurrence of such a process *in vivo* has yet to be demonstrated. We have recently shown that certain strains of *P. freudenreichii*, including TL133, are able to survive and to be metabolically active in the gastrointestinal tract of HMA rats\(^{(26)}\). This strain also produces metabolites that induce colon cancer cell apoptosis *in vitro*. We thus investigated the pro-apoptotic effect of TL133 at an early stage of carcinogenesis. Colonic epithelial apoptosis and proliferation were quantified in HMA rats consuming TL133 on a daily basis, 48 h after the induction of carcinogenesis with 1,2-dimethylhydrazine (DMH).

### Materials and methods

#### Chemicals

When not specified, chemicals were purchased from Sigma-Aldrich (Saint-Quentin-Fallavier, France).

#### Bacterial strain

*P. freudenreichii* subsp. *shermanii* strain TL133 was kindly provided by Laboratoires Standa (Caen, France) as a freeze-dried powder in sealed pots which contained approximately 4 x 10\(^{11}\) colony-forming units (CFU)/g to be used in the present study. The bacterial cells were kept at −20°C until the moment of use. Before their administration to rats, the powdered bacterial cells were dispersed in 20 ml of sterile saline (Aguettant, Alcyon, Paris, France) and gently stirred until a homogeneous suspension was achieved. The final concentration of the bacterial suspension was 2 x 10\(^{10}\) CFU/ml.

#### Animals and diet

Male Fischer 344 rats (\(n=24\)), aged 2 months at the start of the experiment (mean weight 208 ± 3 g), were used. They were born germ-free and bred in germ-free conditions in the Germ-Free Rodent Breeding Facilities of UR910 Ecologie et Physiologie du Système Digestif (INRA, Jouy-en-Josas, France), according to previously established methods\(^{(27)}\). Throughout the study, animals were housed in sterile Plexiglas isolators (Ingénia, Vitry-sur-Seine, France) maintained in a controlled light–dark cycle (lights on from 07.00 to 19.00 hours), at a controlled temperature (20–22°C) and humidity (45–55 %). They were given free access to sterilized tap water and to a pelleted semi-synthetic diet (SAFE, Augy, France) sterilized by γ-irradiation at 45 kGy (IBA Mediris, Fleurus, Belgium). In order to reproduce the diversity of a human-type diet, lipids and proteins of both animal and plant origins, as well as saccharose and cooked starch, were included. The diet consisted of 29 % (w/w) mashed potato, 29 % maize starch, 5 % saccharose, 5 % casein, 12 % soya isolate (Nurish 1500, DuPont Protein Technologies, Paris, France), 3 % maize oil, 3 % lard, 0.015 % cholesterol, 6 % cellulose, and 8 % mineral and vitamin additives\(^{(26)}\). Analytical compounds of DM were crude proteins 18 %, crude fat 8 %, ash 6 % and carbohydrates 68 % (energy 19-33 MJ/kg DM; Eurofins Scientific Analytics, Nantes, France). Food intake and body weight were recorded weekly and at death. All procedures were carried out in accordance with the European guidelines for the care and use of laboratory animals and with permission 78-58 of the French Veterinary Services to use rats for this type of experiment.

At the start of the experiment, all rats were orally administered 1 ml fresh faecal suspension made from the stools of a healthy adult human subject. This subject had followed a normal diet for 3 weeks but excluded the ingestion of fermented products containing PAB. Fresh stools (2 g) were transferred to an anaerobic glove box and dispersed in 200 ml brain heart infusion broth (Difco, Becton Dickinson, Le Pont de Claix, France). The suspension was subsequently transferred to the isolators and administered to the rats using a sterile stainless-steel stomach tube. Then 3 weeks were given to allow the microbe to settle in the digestive tract and the rats’ physiology to adapt to the new bacterial status.

#### Experimental design

The HMA rats were randomly allocated into four groups, namely PAB–DMH−, PAB+DMH−, PAB−DMH+ and PAB+DMH+, which were housed in four distinct isolators (six animals per group, two animals per cage). Rats assigned to the PAB+ groups were gavaged daily for 18 d with 2 x 10\(^{10}\) CFU PAB suspended in 1.0 ml physiological saline, while PAB− groups received 1.0 ml physiological saline alone. On day 13 of PAB administration, animals received oral gavage either two doses of DMH (25 mg/kg body weight dissolved in physiological saline as described previously\(^{(28,29)}\)) or 4 d apart (DMH+ groups), or two sham administrations of physiological saline (DMH− groups). DMH was given 4 h after PAB gavage to avoid a possible direct interaction between PAB and carcinogen during the bolus transit. All rats were killed by CO\(_2\) asphyxiation 48 h after the second DMH administration. The caecum was removed, the caecal pH was measured and the content was weighed. One aliquot of caecal content was used immediately for enumeration of PAB and the remaining part was distributed into several vials stored at −80°C for SCFA analysis. The colon was removed intact by excision at the caeco-colonic junction and at the pelvis and gently flushed with PBS (pH 7-4) to remove residual bowel contents. The colon was divided into three parts of equal length, namely...
proximal, mid and distal. Tissue samples (8 mm long) were excised from distal and mid parts and fixed for 24 h in 4% formalin for analysis of apoptotic and proliferation levels in the crypt epithelium as described later.

**Enumeration of propionibacteria in intestinal samples**

Freshly collected faeces (before the beginning of PAB administration and 1 d before killing) and caecal contents were immediately dispersed in a dilution medium (casein enzymatic hydrolysate 2 g/l, yeast extract 2 g/l, NaCl 5 g/l, KH$_2$PO$_4$ 1 g/l, pH 7.0), and 1.0 ml of this 10-fold (w/v) suspension was used for enumeration of PAB. Samples from serial 10-fold dilutions were poured into Pal-Propiobac selective agar (Laboratoires Standa) with added metronidazole (4 mg/l) for the enumeration of PAB in samples of intestinal origin, as described previously. Plates were then incubated anaerobically at 37°C for 1 week prior to colony counting. Results were expressed as log CFU/g faeces or caecal content.

**SCFA analysis in caecal samples**

Samples were water-extracted and proteins were precipitated with phosphotungstic acid. A volume of 0.1 μl of the supernatant was analysed as to SCFA on a gas–liquid chromatograph (Auto-system XL; Perkin Elmer, Saint-Quentin-en-Yvelines, France) equipped with a split-splitless injector, a flame-ionisation detector and a capillary column (15 m × 0.53 mm, 0.5 μm) impregnated with SP 1000 (FSCAP Nukol; Supelco, Saint-Quentin-Fallavier, France). Carrier gas (He) flow rate was 10 ml/min and inlet, column and detector temperatures were 175, 100 and 280°C, respectively. 2-Ethylbutyrate was used as the internal standard. Samples were analysed in duplicate. Data were collected and peaks integrated using the Turbochrom v6 software (Perkin Elmer, Courtaboeuf, France).

**Assessment of crypt cell apoptosis**

Apoptosis was evaluated by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labelling (TUNEL) method using the In situ Cell Death Detection Kit (Roche Diagnostics, Penzberg, Germany). This method allows for the detection and quantification of apoptotic cells, based on labelling of DNA strand breaks generated during apoptosis. Sections (3 μm thick) from paraffin-embedded colons were mounted on electrostatic-treated slides (Super-frost® Plus; WWR, Fontenay-sous-Bois, France). Sections were then deparaffinised with toluene, hydrated through a graded series of ethanol in distilled water. To unmask PCNA protein, tissue sections were immersed in citric acid buffer, pH 6.0 (Dako REAL Target Retrieval Solution; Dako, Glostrup, Denmark) for 40 min. The slides were washed twice in PBS containing 0.05% Tween 20, treated for 10 min in 10% hydrogen peroxide to block endogenous peroxidase and rinsed with PBS. The slides were then incubated for 30 min at room temperature in a humid chamber with the primary antibody (anti-PCNA mouse monoclonal; Interchim, Montluçon, France) diluted 1:300 in PBS. The slides were washed twice in PBS and covered with a biotinylated universal secondary antibody (RTU Vectastain Universal Elite ABC Kit; Vector Laboratories). Immunohistochemical staining was performed in a humid chamber for 30 min using the avidin-biotin immunoenzymatic antigen detection system (RTU Vectastain Universal Elite ABC Kit). After this period slides were rinsed twice in PBS and covered with diaminobenzidine solution for 10 min to develop labeling. The slides were then counterstained with Mayer’s haematoxylin and rinsed for 2 min in running tap water before dehydration and coverslip mounting.

The number of PCNA-positive cells (only cells with dark brown-stained nuclei were considered PCNA-positive) and the total number of cells per crypt (i.e. number of cells from the bottom to the top of the crypt appearing in the section) were counted in twenty longitudinally well-oriented and visible entire crypts per colonic region (mid and distal colonic sections) under a light microscope (magnification × 100). The samples were evaluated in a blind manner as to avoid bias. Proliferative activity was calculated as the mean number of PCNA-positive cells divided by the mean number of total cells multiplied by 100.
Statistical analysis

The experiment was analysed as a 2 2 factorial design, using a two-way ANOVA. The terms analysed as treatments in the ANOVA model were PAB, DMH and PAB DMH. Where ANOVA indicated significant effects, paired means were compared using the Student–Newman–Keuls post hoc test. Statistical significance was set at P < 0.05. Calculations were performed using the Statview® software, version 5.0 (SAS Institute, Cary, NC, USA). All data are expressed as mean values with their standard errors (n 6).

Results

General observations

No observable difference in the rats’ health status was noticed during the experiment. The administration of PAB had no significant effect on body weight gain between animal groups of the same experiment (78 (SEM 1) g/rat). Thus, the rats’ body weight was similar among groups by the end of the experiments (285 (SEM 3) g).

Propionibacteria survival in the gastrointestinal tract

Dairy PAB were undetectable on selective medium in the faeces of all rats at the beginning of the experiment. In the PAB groups, they remained undetected throughout the entire experiment. In the PAB+ groups, the faecal concentration of PAB reached 7·75 (SEM 0·06) log CFU/g after 15 d of consumption of P. freudenreichii TL133 at a dose of 10·3 log CFU/rat per d. Three days later, at the time of killing, the caecal concentration of PAB was 6·86 (SEM 0·07) log CFU/g caecal content.

Caecal fermentation variables

No significant difference in caecal pH was observed between PAB− and PAB+ groups, whether the rats were treated or not with the chemical carcinogen (Table 1). With regard to SCFA, no significant difference was detected between groups. We observed a slight but non-significant increase in the relative proportions of propionate and valerate in the PAB+DMH+ group compared to the PAB−DMH+ group.

Effect of Propionibacterium freudenreichii TL133 on the colonic mucosa

Oral dosing with PAB and/or with the carcinogen DMH did not induce any significant difference in the number of total cells per crypt across the entire colon. The mean number of cells counted in randomly chosen crypts of whole colons (forty crypts counted per rat, six per group) was 59·1 (SEM 0·8) cells. No variation of crypt length was thus shown, allowing for the comparison of groups in terms of apoptotic and proliferative activities.

Effect of Propionibacterium freudenreichii TL133 on colonocyte apoptosis

While apoptosis mainly occurred in the upper crypt zone in healthy colons (DMH− rats), apoptotic events were observed in the entire length of crypts, including the proliferative and the differentiation zones, when rats were treated with DMH. Examples of crypts observed in the distal colon are shown in Fig. 1 (A). No characteristic feature of necrosis was observed in the crypts, regardless of the colonic region and of the rat group.

| Table 1. Effect of Propionibacterium freudenreichii TL133 supplementation on the caecal pH, SCFA concentrations and relative proportions of the SCFA* (Mean values with their standard errors for six rats per group) |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | PAB−            | PAB+            | PAB−            | PAB+            |
| Caecal pH       | 6·81 (0·07)     | 6·71 (0·05)     | 6·64 (0·06)     | 6·80 (0·05)     |
| SCFA concentration (μmol/g) |                 |                 |                 |                 |
| Acetate         | 19·08 (1·45)    | 19·38 (2·16)    | 19·41 (0·99)    | 18·42 (1·42)    |
| Propionate      | 3·50 (0·21)     | 3·52 (0·23)     | 3·53 (0·21)     | 3·71 (0·27)     |
| Butyrate        | 2·28 (0·27)     | 2·22 (0·28)     | 2·29 (0·35)     | 2·16 (0·35)     |
| Valerate        | 0·13 (0·01)     | 0·09 (0·03)     | 0·09 (0·01)     | 0·14 (0·01)     |
| Caproate        | 0·08 (0·02)     | 0·08 (0·02)     | 0·08 (0·03)     | 0·07 (0·01)     |
| BCFAs           | 0·53 (0·04)     | 0·42 (0·06)     | 0·46 (0·03)     | 0·53 (0·02)     |
| Total SCFA      | 25·61 (1·80)    | 25·72 (2·45)    | 26·15 (1·39)    | 25·02 (2·03)    |
| Relative SCFA proportion (%) |                 |                 |                 |                 |
| Acetate         | 74·37 (0·79)    | 74·79 (2·04)    | 74·33 (1·49)    | 73·73 (0·45)    |
| Propionate      | 13·80 (0·63)    | 14·12 (1·26)    | 14·37 (0·38)    | 14·89 (0·37)    |
| Butyrate        | 8·89 (0·85)     | 8·56 (0·52)     | 9·77 (1·10)     | 8·37 (0·72)     |
| Valerate        | 0·52 (0·04)     | 0·42 (0·16)     | 0·34 (0·02)     | 0·56 (0·07)     |
| Caproate        | 0·32 (0·07)     | 0·37 (0·13)     | 0·29 (0·09)     | 0·27 (0·03)     |
| BCFAs           | 2·10 (0·12)     | 1·74 (0·32)     | 1·79 (0·16)     | 2·18 (0·20)     |

BCFAs, branched-chain fatty acids; DMH+, with 1,2-dimethylhydrazine; DMH−, without 1,2-dimethylhydrazine; PAB+, with propionibacteria; PAB−, without propionibacteria.

* For details of procedures, see Materials and methods.
The administration of *P. freudenreichii* TL133 alone did not increase the number of apoptotic cells in healthy colonic mucosa, as shown in Fig. 1 (B). Indeed, the number of apoptotic cells per crypt in the PAB−DMH− group was close to that of basal apoptotic level (PAB−DMH− group), both in mid and distal colon. The number of apoptotic events per crypt was 0.09 (SEM 0.02) in both colon regions of the PAB−DMH− group, and ranged from 0.06 (SEM 0.02) in the distal colon to 0.11 (SEM 0.02) in the mid colon of the PAB+DMH+ group. Thus, PAB supplementation did not modify the apoptotic cell number in healthy colonic mucosa.

Conversely, oral administration of DMH increased the number of apoptotic cells per crypt from 0.09 (SEM 0.02) in the whole colon to 0.36 (SEM 0.05) and 0.42 (SEM 0.08) in the mid and distal colons, respectively. Administration of PAB further raised these apoptotic cell numbers up to 0.68 (SEM 0.05) and 0.71 (SEM 0.05) in the mid (P<0.01) and distal (P<0.01) colons, respectively.

In order to determine in which crypt zone PAB administration induced apoptosis of DMH-damaged cells, the crypts were divided in three equal zones (lower, middle and upper) and apoptotic events were counted. Fig. 2 shows the spatial distribution of apoptotic cells in crypts of the mid (A) and distal (B) colon of DMH+ rats. The administration of PAB increased the number of apoptotic events in all crypt zones of both colon regions, especially in the middle crypt zone where apoptotic activity was maximal compared to its PAB− counterpart. In the mid colon, the induction of apoptosis by PAB was more efficient in the middle and upper crypt zones than in the lower zone. In this region of the colon, 0.38 (SEM 0.02) apoptotic cells were found in the middle crypt zone of PAB+DMH+ rats v. 0.21 (SEM 0.02) in PAB− counterparts (P<0.01). In the distal colon, the induction of apoptosis by PAB was increased in all crypt zones, especially in the middle crypt zone in which 0.39 (SEM 0.06) apoptotic cells were counted v. 0.13 (SEM 0.02) in the PAB−DMH+ group (P<0.01).

**Effect of Propionibacterium freudenreichii TL133 on the proliferative activity of colonocytes**

In order to assess the effect of *P. freudenreichii* TL133 on the proliferation of crypt cells, we scored the PCNA labelling...
index by immunohistochemistry. In the DMH− groups, no proliferative cells were observed in the upper zone of the crypts, as shown in Fig. 3 (A). All the proliferative cells were encountered in the lower two-thirds of the crypts. Contrastingly, DMH treatment caused an increase of the proliferative cell number localised in the upper two-thirds of the crypts, either in the mid or the distal colon. Thus, the proliferative zone extended from the bottom up to the luminal part of the crypts.

Proliferative index values were very similar between the mid and distal colon for each group, respectively (Fig. 3 (B)). In the mid colon of DMH− rats, the basal proliferative index was 56·3 (SEM 1·1) % in the PAB− group and 58·3 (SEM 0·6) % in the PAB+ group. In the distal colon, it reached 56·9 (SEM 0·8) % and 57·7 (SEM 1·7) % in the PAB− and PAB+ groups, respectively.

DMH treatment induced a 20 % increase of the proliferative index in both colon regions. In the mid colon, the proportion of PCNA positively labelled cells was similar in all rats: 74·9 (SEM 1·2) % in the PAB− group v. 75·9 (SEM 0·8) % in the PAB+ group. In the distal colon, the administration of PAB significantly decreased DMH-induced proliferation; indeed, the proliferative index was 76·8 (SEM 1·2) % v. 72·1 (SEM 1·7) % for the PAB− and PAB+ groups, respectively (P<0·01).

Discussion

The colonic epithelium is a constantly renewing tissue, containing cells at different stages of proliferation and differentiation aligned in an orderly pattern along the crypt continuum. The sizes of the colon proliferation and maturational compartments are maintained within precise boundaries by several cell-homeostasis mechanisms, including the control of proliferation, growth arrest, differentiation and apoptosis

In contrast, cancer is a disease which is characterised by an accumulation of cells that can result from either an increased proliferation or from a failure of cells to undergo apoptosis in response to appropriate stimuli

One mechanism by which suppressing agents might act is by inducing previously initiated cells to follow the apoptotic pathway, causing their deletion from the tissue and thus preventing clonal expansion of the neoplastic lesion. With the aim of evaluating the potential of P. freudenreichii as such a suppressing agent, we used a well-known model of DMH-induced colon carcinogenesis in HMA rats. HMA rats constitute a now well-validated model for experimental studies aimed at evaluating the effects of functional foods, including probiotics, in gastrointestinal physiology. The impact of a food component may depend on its utilisation or modification by the resident intestinal microbiota. Moreover, the activity of a probiotic may be modulated by the presence of this microbiota. HMA rats were previously used to evidence the adaptation of P. freudenreichii TL133 and its metabolic activity within the intestine, taking into account both the presence of a human colonic microbiota and its modulation by the probiotic. DMH-induced tumourigenesis in the rat colon is a prolonged multistage process, which shares many of the kinetic, histopathological and molecular characteristics of tumourigenesis in the human colon.

To study the potential protective effects of P. freudenreichii TL133 strain on apoptosis and on the proliferation of colonic mucosa at an early stage of carcinogenesis, we used a 48 h exposure to DMH before killing, as described previously.

Indeed, administration of the carcinogen leads to an immediate inhibition of mitosis associated with an acute apoptotic response, detected as soon as 6 h after DMH treatment and which may last up to 5 d in the rodent colon. Before exposure to the carcinogen, rats were gavaged with P. freudenreichii TL133 for 12 d in order for them to attain a steadily high and metabolically active propionibacterial population in the gastrointestinal tract.

In the present study, we demonstrated the ability of P. freudenreichii TL133 to increase apoptosis of DMH-damaged cells at an early stage of malignant transformation in HMA rats. Considering that DMH treatment induces pre-neoplastic lesions in the mid and distal regions of the colon, we did
not investigate apoptosis and proliferation in the proximal region. In both mid and distal colonic regions, P. freudenreichii significantly enhanced the apoptotic death of DMH-damaged epithelial cells. The observed increase in apoptosis was similar in magnitude to that previously reported by Smith et al. (23) in the mid colon of rats fed with sinigrin after the same time of treatment with DMH. However, they, as well as Latham et al. (21), reported a smaller number of apoptotic cells in the distal region compared to that found in the mid region in conventional rats, a difference that we did not observe in HMA rats. In these aforementioned studies, apoptosis was quantified using morphological criteria, while in the present study it was assessed using the TUNEL method, which does not allow for the detection of cells at early stages of apoptosis, before the occurrence of DNA fragmentation. Therefore, apoptosis could have been underestimated in the present study. On the other hand, the TUNEL method may detect necrotic cells containing damaged DNA (47) but no typical sign of necrosis, such as inflammation, was observed in the colon of the rats used in the present study. We also assessed the distribution of apoptotic cells within the colonic crypt. In a healthy colon, 80% of apoptosis takes place at the upper third of the crypt, none at its middle and rarely, if ever, in the basal region (48). In contrast, in DMH-treated rats, the administration of PAB increased the number of apoptotic cells in all crypt zones but particularly in the lower and middle parts, where normally apoptosis does not occur. Similarly, other protective compounds increase DMH-induced apoptosis in the lower parts of the crypt (21,23). Stem cells, which are especially sensitive to treatment with carcinogens, are located in these parts. PAB-induced apoptosis could specifically target cells mutated by carcinogens. Indeed, no sign of apoptosis was observed in the presence of PAB alone. Furthermore, in rats treated with DMH, we observed an increase of the proliferative index in the upper zone of the crypt, that is to say in the differentiation zone, where proliferation normally does not occur. Potten (48) reported that exposure to a chemical carcinogen leads to an immediate inhibition of mitosis, followed by a recovery, which is often associated with a displacement of mitosis to the upper region of the crypt. Proliferating cells were detected using PCNA immunolabelling. This protein has been reported to be stable and 30–40% of its total initial amount remains present after 24 h of quiescence in 3T3 cells (49). This may have been shown to produce nitric oxide (53), known to be an inducer of apoptosis (54), in addition to SCFA.

Conclusion

P. freudenreichii TL133, a probiotic bacterium previously shown to induce apoptosis of cancer cells in vitro, was shown here for the first time to induce apoptosis of colon cells in vivo. The induction of apoptosis occurred only in animals treated with DMH, suggesting that this induction specifically targets damaged cells. Altogether, the present data indicate that dairy PAB may help in the elimination of damaged cells by apoptosis within the colon epithelium. This suggests a protective role against colon cancer, which should be further confirmed by in vivo carcinogenesis long-term assays aimed at determining their effect on colorectal tumour incidence.

Acknowledgements

The authors acknowledge A. Bouclet (UR910 Ecologie et Physiologie du Système Digestif, Jouy-en-Josas, France) and S. Parayre (UMR1253 Science et Technologie du Lait et de l’Œuf, Rennes, France) for technical assistance as well as Dr A. S. de Lajarte-Thirouard for her expertise in morbid anatomy. The authors thank John McCulloch for revising and correcting the English language. This work has been supported by a grant from CRITT Santé Bretagne. A. L. was the recipient of a doctoral fellowship, 50% from INRA and 50% from the company Laboratoires Standa. A. B. and M. B. participated with A. L. in microbiological analysis and in animal handling, killing and dissection, and with C. P. in SCFA analysis. P. B. trained A. L. in morbid anatomy and histology. S. R. designed and supervised the study and performed the statistical analysis and G. J. supervised the PhD thesis. The authors declare no conflicts of interest.

References


22. Le Leu RK, Brown IL, Hu Y, 


